DrugPatentWatch Database Preview
Endo Pharms Inc Company Profile
» See Plans and Pricing
What is the competitive landscape for ENDO PHARMS INC, and what generic alternatives to ENDO PHARMS INC drugs are available?
ENDO PHARMS INC has five approved drugs.
There are fourteen US patents protecting ENDO PHARMS INC drugs.
There are two hundred and thirty-six patent family members on ENDO PHARMS INC drugs in forty-three countries and four supplementary protection certificates in four countries.
Summary for Endo Pharms Inc
| International Patents: | 236 |
| US Patents: | 14 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Endo Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Pharms Inc | NASCOBAL | cyanocobalamin | SPRAY, METERED;NASAL | 021642-001 | Jan 31, 2005 | RX | Yes | Yes | 7,879,349 | Start Trial | Y | Start Trial | |||
| Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | AB | RX | Yes | Yes | 7,101,576 | Start Trial | Start Trial | |||
| Endo Pharms Inc | AVEED | testosterone undecanoate | INJECTABLE;INTRAMUSCULAR | 022219-001 | Mar 5, 2014 | RX | Yes | Yes | 7,718,640 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Endo Pharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 5,145,684 | Start Trial |
| Endo Pharms Inc | MEGACE ES | megestrol acetate | SUSPENSION;ORAL | 021778-001 | Jul 5, 2005 | 6,592,903 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ENDO PHARMS INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
| ➤ Subscribe | Injection | 250 mg/mL | ➤ Subscribe | 2014-06-11 |
International Patents for Endo Pharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2518910 | Start Trial |
| Taiwan | 200403079 | Start Trial |
| Austria | 539737 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Endo Pharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0694547 | SPC/GB02/027 | United Kingdom | Start Trial | PRODUCT NAME: 2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)-METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE HYDROCHLORIDE (VALGANCICLOVIR HYDROCHLORIDE); REGISTERED: NL RVG 25992 20010920; UK PL 00031/0599 20020425 |
| 0694547 | C300071 | Netherlands | Start Trial | PRODUCT NAME: VALGANCICLOVIR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: RVG 25992 20010920 |
| 0694547 | 2002/028 | Ireland | Start Trial | PRODUCT NAME: VALGANCICLOVIR (2-(2-AMINO-1,6-DIHYDRO-6-OXO-PURIN-9-YL)- METHOXY-3-HYDROXY-1-PROPANYL-L-VALINATE) AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; NAT REGISTRATION NO/DATE: 50/150/1 20020913; FIRST REGISTRATION NO/DATE: NL 25992 20010920; PAEDIATRIC INVESTIGATION PLAN: P/0220/2013 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
